Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Medicine and Dentistry

• Patient 40%
• Therapeutic Procedure 25%
• Infection 20%
• Severe Acute Respiratory Syndrome Coronavirus 2 15%
• COVID-19 15%
• Adverse Event 10%
• Hospital 10%
• Intention-to-Treat Analysis 10%
• Amaurosis 10%
• Inhalation 5%
• Symptom 5%
• Chemotherapeutic Agent 5%
• Adult 5%
• Oxygen 5%
• Statistical Analysis 5%
• Hazard Ratio 5%
• Diseases 5%
• Inpatient 5%
• Supplementation 5%
• Odds Ratio 5%
• Headache 5%
• Drug 5%
• Reverse Transcription Polymerase Chain Reaction 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Infection 20%
• Blindness 10%
• Death 10%
• Adverse Event 10%
• Clinical Trial 10%
• Symptom 5%
• Headache 5%
• Oxygen 5%
• Diseases 5%
• Drug 5%